(Applicant's Description) The University of California San Francisco Cancer Center is requesting support from the National Cancer Institute for three years. The Cancer Center consists of 11 established programs, a developing program in Gastrointestinal Oncology, and five shared resources as well as an Administrative Core. The Center also has developing efforts in thoracic oncology and cancer risk. The research programs include: Breast Oncology, Neurologic Oncology, Oral/Head and Neck Oncology, Genitourinary Oncology, Gynecologic Oncology, HIV-Related Malignancies, Hematopoietic Malignancies, Cutaneous Oncology, Cell Cycle Disregulation, Cancer Genetics, and Tobacco Control. The shared resources include Biostatistics, Clinical Research Support Services, Tissue, Transgenic/Targeted Mutagenesis, and a multi-faceted Molecular Diagnostics Core with components in cytometry, genome analysis, and cytology. Developmental funds are being requested to initiate a microarrays component of the Molecular Diagnostics Core. The University of California San Francisco Cancer Center has a research base that includes $21,489,681 in direct costs from the National Cancer Institute, $18,608,907 in direct costs from other NIH institutes, $558,763 in direct costs from the ACS, $349,336 in direct costs from the NSF, and $6,906,970 in direct costs from other peer-reviewed sources. The institution has committed more than $100 million to the development of the Center, including construction of a new 50,000-square-feet research building and 88,000-square-feet clinical building, and funds to recruit at least 10 new faculty to strengthen and enhance cancer research. The major goal of the University of California San Francisco Cancer Center is to translate new approaches to cancer prevention, detection, and treatment into the area of clinical research, where they will be tested and evaluated efficiently and thoroughly. The multidisciplinary nature of the research programs within the Center should facilitate this process by focusing research efforts on clinically relevant issues, and ensuring that clinical efforts have a strong research foundation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA082103-01
Application #
2879629
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1999-08-05
Project End
2002-07-31
Budget Start
1999-08-05
Budget End
2000-07-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications